/NVTA

NVTA Stock - Invitae Corporation

Q: What is the analyst price target for NVTA?

Analyst price target information is not currently available for NVTA.

Q: What is NVTA's market cap?

Market capitalization information is not currently available for NVTA.

Healthcare|Medical - Diagnostics & Research|NYSE

$0.02-35.59%

$0.01 (-35.59%) • Feb 14

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+51215.8%upside

Target: $9.75

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NVTA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.59

52W High$2.34

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$516.30M	$460.45M	$279.60M	$216.82M	$147.70M
Gross Profit	$99.05M	$111.78M	$81.32M	$98.72M	$67.59M
Gross Margin	19.2%	24.3%	29.1%	45.5%	45.8%
Operating Income	$-714,236,000	$-778,287,000	$-652,172,000	$-244,112,000	$-122,557,000
Net Income	$-3,106,293,000	$-379,006,000	$-608,870,000	$-241,965,000	$-129,355,000
Net Margin	-601.6%	-82.3%	-217.8%	-111.6%	-87.6%
EPS	$-13.18	$-1.80	$-4.52	$-2.66	$-1.94

Company Overview

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

40%

Sell / Underperform

60%

Analyst Consensus🔴 Bearish

0 Bullish5 Neutral/Bearish

Price Targets

Average Target

↑ 10426.3% Upside

Now

Low

Average

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 5th 2023	JP Morgan	Resumed	Underweight	-
May 15th 2023	Raymond James	Downgrade	Underperform	-
January 31st 2023	Goldman	Downgrade	Sell	$2
August 25th 2022	Credit Suisse	Initiation	Underperform	$1
August 10th 2022	JP Morgan	Downgrade	Underweight	-
July 26th 2022	Cowen	Downgrade	Market Perform	$2.5← $8
July 21st 2022	Raymond James	Downgrade	Market Perform	-
July 20th 2022	Ladenburg Thalmann	Downgrade	Neutral	-
July 19th 2022	The Benchmark Company	Downgrade	Hold	-
July 19th 2022	SVB Leerink	Downgrade	Market Perform	-
June 3rd 2022	Piper Sandler	Initiation	Underweight	$2.5

Earnings History & Surprises

NVTA

Beat Rate

41%

Last 17 quarters

Avg Surprise

+3.3%

EPS vs Estimate

Beats / Misses

7/10

Last 12 quarters

Latest EPS

$-0.34

Q1 2024

EPS Surprise History

Q2 22

-1.3%

$-0.78vs$-0.77

Q3 22

+8.1%

$-0.68vs$-0.74

Q4 22

+28.8%

$-0.42vs$-0.59

Q1 23

+38.2%

$-0.34vs$-0.55

Q2 23

+9.8%

$-0.37vs$-0.41

Q3 23

+18.9%

$-0.30vs$-0.37

Q4 23

+66.7%

$-0.10vs$-0.30

Q1 24

-13.3%

$-0.34vs$-0.30

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 6, 2024	—	—	—	—
Q3 2024	Aug 6, 2024	—	—	—	—
Q2 2024	May 7, 2024	—	—	—	—
Q1 2024	Feb 27, 2024	$-0.30	$-0.34	-13.3%	✗ MISS
Q4 2023	Nov 8, 2023	$-0.30	$-0.10	+66.7%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.37	$-0.30	+18.9%	✓ BEAT
Q2 2023	May 9, 2023	$-0.41	$-0.37	+9.8%	✓ BEAT
Q1 2023	Feb 28, 2023	$-0.55	$-0.34	+38.2%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.59	$-0.42	+28.8%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.74	$-0.68	+8.1%	✓ BEAT
Q2 2022	May 3, 2022	$-0.77	$-0.78	-1.3%	✗ MISS
Q1 2022	Feb 24, 2022	$-0.74	$-0.81	-9.5%	✗ MISS
Q4 2021	Nov 8, 2021	$-0.69	$-0.81	-17.4%	✗ MISS
Q3 2021	Aug 3, 2021	$-0.65	$-0.85	-30.8%	✗ MISS
Q2 2021	May 4, 2021	$-0.60	$-0.63	-5.0%	✗ MISS
Q1 2021	Feb 17, 2021	$-0.58	$-0.63	-8.6%	✗ MISS
Q4 2020	Nov 5, 2020	$-0.60	$-0.62	-3.3%	✗ MISS
Q3 2020	Aug 4, 2020	$-0.62	$-0.77	-24.2%	✗ MISS
Q2 2020	May 5, 2020	$-0.84	$-0.80	+4.8%	✓ BEAT
Q1 2020	Feb 19, 2020	$-0.60	$-0.63	-5.0%	✗ MISS

Frequently Asked Questions about NVTA

What is NVTA's current stock price?

Invitae Corporation (NVTA) is currently trading at $0.02 per share. The stock has moved -35.59% today.

What is the analyst price target for NVTA?

The average analyst price target for NVTA is $9.75, based on 1 analyst.

What sector is Invitae Corporation in?

Invitae Corporation operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NYSE exchange.

What is NVTA's market cap?

Invitae Corporation has a market capitalization of $0.01 billion, making it a small-cap company.

Does NVTA pay dividends?

No, Invitae Corporation does not currently pay a dividend to shareholders.